Get the Stockscreener App
10.94
1.88%
-0.225
Cybin Inc stock is traded at $10.94, with a volume of 145.54K.
It is down -1.88% in the last 24 hours and up +0.27% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$11.16
Open:
$11.25
24h Volume:
145.54K
Relative Volume:
0.48
Market Cap:
$220.32M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-56.40
EPS:
-0.1939
Net Cash Flow:
$-44.93M
1W Performance:
-0.45%
1M Performance:
+0.27%
6M Performance:
-18.81%
1Y Performance:
-38.32%
1-Day Range:
$10.77
$11.39
1-Week Range:
$10.36
$13.88
52-Week Range:
$6.50
$21.66
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CYBN | 10.94 | 220.32M | 0 | -52.07M | -44.93M | -0.1939 |
| VRTX | 447.41 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.03 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.03 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.69 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish - MSN
Cybin’s Breakthrough: Psychedelic Depression Drug CYB003 Sustains 12-Month Symptom Remission in Major Depressive Disorder - geneonline
H.C. Wainwright reiterates Buy on Cybin stock, sees strong potential for CYB003 in MDD - Investing.com
Breakthrough Therapy Shows Promising Long-Term Results for Depression - Streetwise Reports
Cybin (NYSE:CYBN) Receives Buy Rating from HC Wainwright - MarketBeat
Cybin Reports Positive Phase 2 Data for CYB003 - The Dales Report
Cybin’s CYB003 Shows Promising Results for Depression - TipRanks
Cybin reports sustained depression treatment effects - Investing.com India
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
Cybin posts second-quarter loss widens as clinical trials advance - Green Market Report
Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00 - MarketBeat
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - BioSpace
Cybin to Present Promising CYB003 Study Results - TipRanks
Cybin to Showcase Promising Depression Treatment Progress - TipRanks
Cybin Phase 3 Layout - Green Market Report
CYBNCybin Inc. Latest Stock News & Market Updates - StockTitan
Cybin Inc (CYBN-NE) QuotePress Release - The Globe and Mail
Cybin launches new program phase to treat Major Depressive Disorder | 2024-11-13 | Investing News - Stockhouse Publishing
Cybin’s Phase 3 Trials and Financial Update - TipRanks
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - StreetInsider.com
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Benzinga
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results – Company AnnouncementFT.com - Financial Times
What might RFK Jr’s psychedelic strategy look like? - Proactive Investors USA
Cybin Faces Key Data Readouts For Major Depressive Disorder, Generalized Anxiety Disorder - RTTNews
Learn to Evaluate (CYBN) using the Charts - Stock Traders Daily
Cybin Inc. (NYSE:CYBN) Stake Lowered by Rosalind Advisors Inc. - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 0.2%Here's What Happened - MarketBeat
Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma
PDS Planning Inc Sells 885,540 Shares of Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - BioSpace
Cybin to Highlight Innovations at Health Summit - TipRanks
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
(CYBN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program - MSN
Cybin secures patent for CNS disorder treatment candidates - Investing.com
Cybin announces grant of patent in support of CYB005 phenethylamines program - TipRanks
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Sanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin (NYSE:CYBN) Trading Down 7.4%What's Next? - MarketBeat
Cybin (NYSE:CYBN) Stock Price Up 9.7%What's Next? - MarketBeat
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha
(CYBN) Trading Signals - Stock Traders Daily
Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha
Cybin (NYSE:CYBN) Shares Gap DownWhat's Next? - MarketBeat
Cybin (OTCMKTS:CYBN) Trading 1.5% HigherHere's What Happened - MarketBeat
Cybin (NYSE:CYBN) Shares Up 5.4%Still a Buy? - MarketBeat
(CYBN) Investment Analysis and Advice - Stock Traders Daily
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat - MSN
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Cap:
|
Volume (24h):